Dolutegravir and Risk of Neuropsychiatric Adverse Events: A Pharmacogenetic Study. - De Greef J; Yombi JC; Vincent A; Vandercam B; de Timary P; Boland L; Philippeau M; Panin N; Elens L; Haufroid V; Belkhir L (The Journal of infectious diseases, 2025)